Personalized medicine employing patient-based tailor-made therapeutic drugs is taking over treatment paradigms in a variety of fields in oncology and the central nervous system. The success of such therapies is mainly dependent on efficacious therapeutic drugs and a selective imaging probe for identification of potential responders as well as therapy monitoring for an early benefit assessment. Molecular imaging (MI) is based on the selective and specific interaction of a molecular probe with a biological target which is visualized through nuclear, magnetic resonance, near infrared or other methods. Therefore it is the method of choice for patient selection and therapy monitoring as well as for specific endpoint monitoring in modern drug development. PET (positron emitting tomography), a nuclear medical imaging modality, is ideally suited to produce three-dimensional images of various targets or processes. The rapidly increasing demand for highly selective probes for MI strongly pushes the development of new PET tracers and PET chemistry.
The 62nd Ernst Schering Foundation Workshop 'PET ChemistryThe Driving Force in Molecular Imaging' is the first in the history of the Foundation devoted to special aspects of the synthesis and characterization of PET tracers. The purpose of the workshop was to gain a deeper insight into the complex applications and emerging technologies in the area of PET chemistry. New inventions in this field have a strong impact on MI, preclinical and clinical research, new therapeutic drug development, clinical routine applications and new chemical concepts.
The contributions from the invited experts that are compiled in this book demonstrate the focus and the large investment of effort over the last decade towards the advancement of PET chemistry as the cornerstone of MI today. New ideas in this exciting field translate into practical benefit very quickly. Scientific aspects covered by the workshop included reflections on a variety of PET isotopes such as 11 C, 68 Ga, 64 Cu, 86 Y, 76 Br, 77 Br, 124 I and their impact on the MI field. The main focus was put on 18 F, the 'workhorse' of PET. The contributions embraced a broad spectrum of new technical features such as the application of microwaves, microreactors and modules in the synthesis and development of new PET tracers.
The open atmosphere that prevailed during interdisciplinary discussions, and the dedication towards the goal of advancing the shared field of expertise, led to a profound contribution to PET chemistry.
We wish to express our sincere gratitude to all participants for their contributions to both the workshop and to this book. We are also grateful to the Schering Research Foundation for the generous support in making the workshop a great success. Abstract. Molecular imaging has become a very popular term in medicine and can be interpreted in many different ways. It is argued that a correct definition should be 'in vivo imaging of biological processes with appropriate molecular probes'. The real challenge in molecular imaging therefore is the search for the 'optimal' molecular imaging probes. It is discussed that nuclear, optical and magnetic probes can be used. However, only PET probes have the high sensitivity to be applied generally. To develop PET probes efficiently, methods for the in vitro and in vivo characterization are discussed and alternatives compared. Some open questions with respect to the reliability of animal imaging and evaluation of the imaging data will be elucidated.
Introduction
'PET-Chemistry: The Driving Force in Molecular Imaging' -the title of this symposium, is a strong statement about the role of PET chemistry. Consequently many eminent colleagues will discuss at this symposium efficient radiolabeling strategies and techniques for different types of biomolecules and PET radionuclides. It also means that a lot of resources are dedicated to this field, so one must be convinced that the message of this symposium as expressed in this title holds true. It may therefore be wise to ask a few questions in this context at the opening of this symposium.
The first question is about the definition of molecular imaging: What exactly is meant by the term 'molecular imaging'?
This leads us to a second question about molecular probes: Is a molecular probe or more specifically a PET molecular probe (for which we need PET chemistry) the tool to achieve molecular imaging?
Assuming that this is the case we must ask: Do we know how to develop and characterize PET ligands in the most straightforward manner or do we still lack the optimal methodology?
When we obtain molecular images with PET ligands in animal and humans, we present and publish proudly our 'pictures' as part of our results. But do we also have the proper prerequisites and means to accumulate and evaluate these images quantitatively?
Molecular Imaging?
Molecular imaging has become a very popular term in medicine. In the literature and at scientific meetings images are presented under the term 'molecular' -irrespective of the imaging method (CT, US, MRI, BLI or PET) and the information gained from the image. Thus, it appears the broad use of the label 'molecular' has probably less to do with a proper scientific definition than with clever marketing strategies and the expectations of industry and medicine to make an additional profit out of this label. This is the message of an impressive Editorial by U. Haberkorn and M. Eisenhut (Haberkorn and Eisenhut 2005) .
Molecular imaging can theoretically be interpreted in two ways, namely as imaging of molecules or as imaging using molecules (i.e. molecular probes). How is molecular imaging defined in the field of nuclear medicine? Each year at the SNM (Society of Nuclear Medicine) meeting a highlight lecture is given to address novel and relevant results, trends, and an image of the year is selected (Fig. 1) one whereby protein molecules within the cell aggregates are visualized with a confocal microscope, or in which the resolution of molecules in space is studied with scanning near-field optical micrography (Fig. 3 ). With this and many more methods we can get information on various properties of molecules.
Thus it is obvious that in medicine we are not looking for images of molecules, but we are imaging biological processes by using molecular probes or in the words of S.S. Gambhir (in Marx 2005) : "Molecular imaging makes molecular processes visible, quantifiable and trackable over time in a live animal or human". Conclusively, I would define molecular imaging as 'in vivo imaging of biological processes with appropriate molecular probes'.
Molecular Probes?
The real challenge in molecular imaging therefore is the search for the 'optimal' molecular imaging probes followed by the search for the appropriate (imaging) machine. Understanding biology at the molecular level needs molecules, which are part of the biological processes underlying normal or diseased states. The imaging of these molecular probes then must lead to the development of technical devices -tools to detect the signals of specific molecular probes. Imaging strategies are based on the target-specific molecular probes. Imaging methods have been established using nuclear, optical and MR imaging technology.
The functional principles of specific molecular probes are depicted in Fig. 4 . The resultant image of probe localization and concentration (signal intensity) is directly related to its interaction with the target. The choice of a certain imaging modality depends primarily on the specific question to be addressed. Answering those questions requires methods with specific properties on spatial resolution, sensitivity and specificity. The strength and weakness of various methods (CT, US, MRI, BLT, FMT, FRI, PET, SPET) are discussed in many reviews (see, e.g. Rudin 2003 or Contag 2002 . In Table 1 various high-resolution small animal imaging systems are compared. It is obvious that only PET has the sensitivity needed to visualize most interactions between physiological targets and ligands, such as neurotransmitter and brain receptors (imag- ing quality is independent of both the localization of the organ within the body and of the distance of the organ to the body surface). Therefore, if the question concerns monitoring drug distribution, pharmacokinetics and pharmacodynamics for most organs (e.g. the brain) PET is the only choice as a nuclear imaging technique.
Development of New Molecular PET ProbesPermeation of the Blood-Brain Barrier?
Choosing the right target and defining the purpose of the molecular probes is a tedious process, but not part of this introduction. In this context, I would like to stress one point taken from a review by Bill Eckelman (Eckelmann et al. 2005 ). There he discusses neurotransmitter systems for which multiple radiolabeled molecular probes have been developed. He concludes that although the rationale for the development of these radioligands often refers to a target disease, few have actually demonstrated an impact on patient care. Once a desired PET molecular probe (PET ligand) is defined and synthesized, the in vitro and in vivo characterization should proceed in the most efficient way such that a 'go' or 'no go' decision is taken as early as possible. For the in vitro characterization, methods exist to validate binding to the target structure, to test stability in blood serum or to identify metabolites. For blood-brain barrier (BBB) permeation many methods have been proposed but the most commonly used method is the partition coefficient logP or logD which, however, is not reliable. The next example demonstrates that lipophilicity does not always predict brain permeation very reliably. Table 2 shows structures of some potential PET-ligands for the metabotropic glutamatergic receptor subtype 5 (mGluR5) with their respective binding affinities and lipophilicity values. This is a selection of some of the ligands we synthesized and evaluated in our group. The use of planar lipid bilayers such as in IAM (immobilizer artificial membrane) chromatography columns or PAMPA (parallel artificial membrane permeability assay; highly porous microfilters coated with phospholipid layers), which mimic the lipid environment found in cell membranes, give some indications about passive transport only. The lipid bilayers are known to be physically unstable and to contain residual solvent molecules. Liposomes have a better physical stability and can be prepared without solvents or other adjuvants (Krämer and WunderliAllenspach 2001) . In the cellular model approach, in vitro techniques typically use a tissue culture model of cerebrovascular endothelial cells (MDCK or Caco2) either alone or cocultured with astroglia. These models are very time consuming and labour extensive (Löscher and Potschka 2005) .
Available in vivo models mostly rely on rodents (mouse, rat, guinea pig), are well described and widely used but lead to ethical issues and overwhelming costs. Non-invasive approaches are imaging technologies that use dedicated platforms such as PET, MRI, or (immuno) histochemistry. Invasive models use, for example, the classical pharmacokinetic analysis (brain extraction, canulation), the intracerebral microdialysis, or the beta-probe method. The β-microprobe system is a local β-radioactivity counter that takes advantage of the limited range of β-particles within biologic tissues to define the detection volume in which the radioactivity is counted (Pain et al. 2004) . The device has been validated for pharmacology studies, some involving coupling with microdialysis and some involving quantitative measurements of cerebral metabolism. The use of two β-microprobes allows simultaneous determination of blood and cerebral tissue-time activity curves after a single injection of a PET tracer in an animal. However, it is highly invasive and requires skilled personnel trained to place plastic catheters in small animals.
Summarizing the methods for evaluating the BBB penetration for drug development purposes, one will notice that none of the published models has yet been adopted by a significant number of research laboratories. Research on BBB models is a relatively young field and there is not a definitive model available:
a. There is no 'golden rule' for approaching brain penetration (such as Lipinski's rule of five). b. Among the BBB permeation or penetration models available, some are often used in parallel (in silico, in vitro and in vivo approaches). c. Currently, the methods preferentially used in predicting drug absorption, are logP, logD data compared to liposome permeation data for membrane translation, and the use of cell-based assays (e.g. monolayers of MDCK cells).
Experimental Imaging Design and Data Evaluation: Limitations and Challenges?
In contrast to human PET imaging, PET data collection in small animals involves immobilization of the animal which is generally attained by anaesthesia during scanning. All anaesthetics have significant effects on the respiratory, cardiovascular and central nervous systems. Therefore, anaesthesia should be administered at a superficial level to reduce the effects on circulation and metabolism. Furthermore, fluctuations in the anaesthetic level among various scans may increase the interindividual variation in tracer uptake, kinetics and metabolism and should thus be kept to a minimum by standardization of anaesthetic regimens. Cross-correlation analyses using biodistribution studies with non-anaesthetized animals can help to assess the impact of the anaesthetic regimen on signal sizes and kinetics. For example, by comparing post-mortem striatal activity concentrations of the D2 receptor ligand [ 18 F]-fallypride in anaesthetized and non-anaesthetized mice a substantial influence of isoflurane anaesthesia on signal sizes was excluded (Fig. 5) . Post-mortem activity concentrations in the striatum differed only by 20% at 63 min and 153 min post-injection (Honer et al. 2004) , being thus in line with a marginal susceptibility of the radiotracer to metabolic breakdown as suggested by a dynamic ROI analysis (Mukherjee et al. 1999) . PET studies in mice and rats without the involvement of anaesthesia remain a major challenge for small animal PET experimentation. So far, PET experiments have been performed in conscious and trained cats or monkeys (Hassoun et al. 2003; Noda et al. 2003; Tsukada et al. 2000; Zimmer et al. 2003) . In a recent study, a non-anaesthetized rat was trained to accept head fixation and scanned for 60 min (Momosaki et al. 2004) . Regarding animal welfare issues and scanning throughput this approach will probably not achieve general acceptance. Furthermore, the effects of the physical and mental stress imposed on the animal by active restraint are not well analysed. Alternatively, a PET system mounted to a rat's head allowed imaging of the conscious rodent brain (Vaska et al. 2004 ) but the practicability and utility of this experimental approach has still to be demonstrated.
Another major challenge in small animal PET imaging affects data processing and quantification. It is crucial to find ways to conduct small animal PET studies with higher efficiency and accuracy. PET imaging involves acquisition of huge data sets and timely PET data reconstruction is desired. Therefore, efficient data management, the use of high performance hardware as well as fast reconstruction algorithms are imperative for higher throughput of scanning experiments in the future. Additionally, PET imaging has the big advantage to allow the distribution of a radiotracer to be measured in quantitative units. However, only limited in-formation is available on the feasibility of achieving absolute quantification in small animal PET imaging. Corrections for attenuation in the animal's body as well as for scattered coincidences have to be implemented in the reconstruction software. Furthermore, calibration factors should be routinely determined and applied to allow conversion between scanner units (counts/voxel/s) and radioactivity concentrations (kBq/ml). Dynamically reconstructed PET data can be further processed and quantified by applying tracer kinetic models. To perform such fully quantitative dynamic PET experiments, information on the time-course of tracer delivery to the tissue is mandatory (for a review see Laforest et al. 2005) .
Another challenge to obtain precise and reliable quantitative PET data involves high intra-study stability and inter-study reproducibility of the imaging experiment. Only a detailed standardized experimental design as well as standardized evaluation techniques avoid the introduction of bias to the analysis and permit one to draw meaningful conclusions from a longitudinal study with repetitive PET scanning experiments. The significance of PET data obtained in mice and rats may be also limited if rodent data shall be translated to the human setting. Species differences in metabolism, protein binding characteristics, and target site density etc. might be considerable and complicate the prediction of whether a successfully characterized PET tracer in rodents can be effectively applied in humans. In order to facilitate the extrapolation of rodent PET data to the clinical situation, the development of meaningful assays (e.g. metabolite analyses using human hepatocytes) represents a major challenge for successful preclinical PET tracer characterization in the future.
Conclusions
Molecular imaging means in vivo imaging of biological processes with appropriate molecular probes. Today only PET has the sensitivity to visualize most physiological interactions in a volume and target-depth independent manner, and in three dimensions. Therefore the real challenge is the search for the specific PET probes, and so PET chemistry is indeed the driving force in molecular imaging. However, besides chemistry some other fields such as pharmacological characterization, animal handling or data evaluation must also be developed further. Abstract. Many experimental and established tracers make fluorine-18 the most widely used radionuclide in positron emission tomography with an increasing demand for new or simpler 18 F-labeling procedures. After a brief summary of the advantages of the nuclide and its major production routes, the basic features of the principal radiofluorination methods are described. These comprise direct electrophilic and nucleophilic processes, or in case of more complex molecules, the labeling of synthons and prosthetic groups for indirect built-up syntheses. While addressing the progress of no-carrier-added 18 F-labeling procedures, the following chapters on more specific topics in this book are introduced. Emphasis is given to radiofluorination of arenes -especially with iodonium leaving groups. Examples of radiopharmaceutical syntheses are mentioned in order to illustrate strategic concepts of labeling with fluorine-18.
Introduction
Concomitant with the increasing variety of biochemical and pharmacological principles applied for molecular imaging and hence with the growing number of chemical compound classes used, there is a permanent demand for new or adapted methods of labeling. Fluorine-18 is the radionuclide most often used for routine diagnosis with positron emission tomography (PET). The preparation and use of 18 F-labeled radiopharmaceuticals and experimental compounds have been summarized in many recent reviews (Lasne et al. 2002; Wester 2003; Coenen 2003; Shiue et al. 2004; Couturier et al. 2004; Adam and Wilbur 2005) . Several chapters in this book deal with the preparation of special classes of compounds, built-up and prosthetic group labeling as well as technical aspects of radiofluorination procedures. Therefore, the focus here will be on the basics of established and newer methods of the primary 18 F-labeling step.
The report on the first production of fluorine-18 originates from 1936 (Snell 1937) and only 4 years later it found use in health related studies on fluoride-adsorption by bone and dentine (Volker et al. 1940) . Its success as routine PET nuclide in diagnosis and pharmacological research is based on its almost perfect chemical and nuclear properties. Fluorine-18 can be produced in good yields, even with low-energy cyclotrons. The half-life of 109.7 min allows time-consuming multi-step radiosyntheses as well as extended PET studies of slower biochemical processes; in addition, it makes shipment possible according to a so-called satellite concept. Thus the supply of clinics without an on-site cyclotron can be ensured. The radionuclide has a low β + -energy of 635 keV, besides 64 Cu the lowest of the PET nuclides, which promises a very high resolution of down to 1 mm in PET images and guarantees minor radiation doses to the patients.
Most commonly fluorine-18 is employed in analoguous fluoroderivatives, where it sterically replaces a hydrogen atom. While the Van der Waals' radii of fluorine (1.35 Å) and hydrogen (1.20 Å) are almost the same, the differences in electronic character of the two elements, however, are very pronounced. For example, replacing a hydrogen in an aliphatic position by fluorine will decrease the lipophilicity by a factor of five while substitution in an aryl group will increase it twofold. Nevertheless, most of the 18 F-labeled compounds are based on the analogy in steric demands of fluorine and hydrogen. The best known example is 2-[
18 F]fluorodeoxyglucose ([ 18 F]FDG), which is the most widely used PET radiopharmaceutical (Gallagher et al. 1978; Reivich et al. 1979) . Also the analoguous amino acid L-2-[
18 F]fluorotyrosine shows metabolic acceptance (Coenen et al. 1989; Couturier et al. 2004 ). This again is true for 6-[
18 F]fluoro-3,4-dihydroxy-l-phenylalanine (6-[ 18 F]fluoro-l-DOPA), a radiodiagnostic for neurodegenerative diseases (Parkinson disease) and for oncology (Shiue et al. 2004; Couturier et al. 2004 ).
Nuclide Production
For fluorine-18 more than 20 nuclear reactions are known as production pathways (Qaim et al. 1993 ), the most common of which are listed in Table 1 20 Ne and 18 O gas targets can be chosen. The major problem in both cases is the adsorption of the produced fluorine-18 on the target walls so that an addition of elemental fluorine to the target gas is mandatory and high molar activities cannot be attained (Hess et al. 18 F reaction is most practical and common process for electrophilic fluorine-18, although production rates are lower.
A recent review on the nuclear data of the 18 O(p,n) 18 F reaction from threshold up to 30 MeV proton energy exhibited higher theoretical production yields than the hitherto accepted data, limited to < 14 MeV. The saturation integral yield calculated from the excitation curve as depicted in Fig. 1 , encourages irradiations up to about E p 20 MeV and relativates the performance data of existing targets (Hess et al. 2001 ).
Direct 18 F-Labeling Methods
In principle, general pathways for the fluorination of organic molecules are transferable from macroscopic organic chemistry to radiochemistry. For fluorine introduction into aromatic organic compounds, preparative organic chemistry generally uses stable diazonium piperidines in the Wallach reaction (Wallach 1886) and solid diazonium tetrafluoroborates in the Balz-Schiemann reaction with better yields (Balz and Schiemann 1927) . These are dediazoniation reactions, where the fluoride re- places a decomposing diazonium moiety. However, in no-carrier-added (n.c.a.) labeling syntheses these reaction types only result in low radiochemical yields (Atkins et al. 1972; Tewson and Welch 1979) . For the Balz-Schiemann reaction the tetrafluoroborate counter anion leads axiomatically to a maximum radiochemical yield (RCY) of only 25% and causes isotopic carrier. Moreover, both reactions are principally of the S N 1-type, thus reactive cations evoke and interact with any nucleophilic species causing many side products. The statistical probability of the reactive intermediates to encounter a [ 18 F]fluoride ion under n.c.a. conditions is marginal and only carrier addition leads to acceptable results (Atkins et al. 1972; Tewson and Welch 1979; Coenen 1989) .
Depending on the production procedure (see Table 1 The former procedures represent direct methods and the latter indirect methods, which in turn are based on the direct methods for 18 F-labeling of the required synthon or prosthetic group.
